PT  - JOURNAL ARTICLE
AU  - TSUTOMU TAKASHIMA
AU  - SHIGEHIKO NISHIMURA
AU  - HIDEMI KAWAJIRI
AU  - YOKO MIZUYAMA
AU  - TAKEO NISHIMORI
AU  - SHIGEHITO YAMAGATA
AU  - SHINYA TOKUNAGA
AU  - KENJI TEZUKA
AU  - SEIKA TEI
AU  - TAKESHI SUNAMI
AU  - KATSUMI IKEDA
AU  - YOSHINARI OGAWA
AU  - SHINICHIRO KASHIWAGI
AU  - SATORU NODA
AU  - NAOYOSHI ONODA
AU  - TETSURO ISHIKAWA
AU  - SHINZOH KUDOH
AU  - MINORU TAKADA
AU  - KOSEI HIRAKAWA
AU  - MASAICHI OHIRA
TI  - An Exploratory Phase II Study of Eribulin Re-challenge After Short Term Therapy of 5-Fluorouracil for HER2 Negative, Advanced or Recurrent Breast Cancer
AID  - 10.21873/anticanres.15315
DP  - 2021 Oct 01
TA  - Anticancer Research
PG  - 5007--5014
VI  - 41
IP  - 10
4099  - http://ar.iiarjournals.org/content/41/10/5007.short
4100  - http://ar.iiarjournals.org/content/41/10/5007.full
SO  - Anticancer Res2021 Oct 01; 41
AB  - Background/Aim: In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients. Patients and Methods: HER2-negative MBC patients who had never received chemotherapy for MBC received first-line ERI for 18 weeks if they did not have disease progression, and then one cycle of S-1 before ERI re-administration. Results: Twelve patients received ERI re-administration. The PFS of re-administered ERI was 13 weeks. Total duration of ERI use was 30 weeks. The incidence and severity of adverse events were consistent with previous reports. Conclusion: In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report.